Highlights
- The a2 Milk Company (ASX:A2M) recorded FY26 revenue of NZD 1.9749bn, up 12.4% YoY.
- FY26 EBITDA declined 2.5% YoY to NZD 284.4mn; underlying EBITDA increased 5.4%.
- China-label formula availability was disrupted in 4QFY26, affecting sales and costs.
- FY27 guidance anticipates mid-single-digit revenue growth and an EBITDA margin around 15%.
The a2 Milk Company Limited supplies branded dairy nutrition products, including infant milk formula, liquid milk and other nutritional products, across China, Australia, New Zealand and the United States. Its FY26 results showed revenue growth alongside supply-chain constraints affecting China-label infant formula and expenditure linked to its manufacturing transition. Shares in The a2 Milk Company (ASX:A2M) closed at AUD 7.00 on 26 October 2026, up approximately 1.30% from the preceding trading session. The company’s recent disclosures place attention on the recovery of formula availability, new product launches and FY27 earnings delivery.
Company Business
The a2 Milk Company (ASX:A2M) markets products containing the A2-type beta-casein protein. Its principal categories are infant milk formula, liquid milk and other nutritional products, with distribution through domestic retailers, cross-border channels and local market partners. China and other Asian markets account for a substantial proportion of sales, while Australia, New Zealand and the United States provide additional exposure.
The business reports regional segments covering China and Other Asia, Australia and New Zealand, and the United States. Manufacturing and sourcing arrangements are material to its operating model. The a2 Pōkeno site in New Zealand is undergoing a transition to support infant formula production, with operational performance influenced by the pace of commissioning and product transfer.
Recent Development
In August 2026, The a2 Milk Company (ASX:A2M) reported that disruption to supply arrangements during 4QFY26 reduced availability of its China-label infant formula products and raised supply-chain costs. Management outlined measures to recover distribution and rebuild sales. The company also indicated that products introduced in recent years contributed more than half of FY26 sales growth, with further launches planned during 1HFY27.
China-label and English-label infant formula follow different commercial channels. The company expects China-label recovery to occur progressively through FY27, while English-label offtake is targeted to improve during the first half. Its proposed actions include product innovation, marketing activity and manufacturing transition work at a2 Pōkeno. These remain operational objectives rather than completed outcomes.
Financial Performance and Sector Context
The a2 Milk Company (ASX:A2M) reported continuing-operations revenue of NZD 1.9749bn in FY26, compared with NZD 1.7572bn in FY25, a 12.4% YoY increase. Reported EBITDA decreased 2.5% YoY to NZD 284.4mn, while underlying EBITDA increased 5.4% YoY to NZD 307.6mn. Continuing-operations net profit after tax declined 5.8% YoY to NZD 207.5mn; underlying profit increased 7.0% YoY to NZD 235.8mn.
Infant milk formula generated approximately NZD 1.334bn in revenue, increasing 4.7% YoY. Liquid milk revenue reached NZD 421.9mn, up 21.8% YoY, while Other Nutritionals contributed approximately NZD 216.1mn. Regionally, China and Other Asia revenue was NZD 1.4476bn, Australia and New Zealand NZD 348.2mn, and the United States NZD 179.0mn. These figures reflect different regional demand conditions and the relative weight of formula and liquid-milk channels.
Net cash at 30 June 2026 was NZD 784.5mn, down from NZD 1.0612bn at the preceding year-end. China’s infant formula market, competitive distribution channels, product registration requirements and cross-border supply arrangements remain material sector considerations. For The a2 Milk Company (ASX:A2M), product availability and manufacturing execution are directly relevant to sales conversion and profitability.
Risks to Consider
Principal risks include further interruptions to China-label infant formula supply, customer demand variations, intense category competition, and delays in recovering retail distribution. The a2 Pōkeno transition can affect production costs and manufacturing efficiency. Foreign-exchange movements, regulatory approvals, import rules and changes in dairy-input costs also influence operating outcomes. The recovery trajectory may differ from management’s planning assumptions.
What to Watch Next
The a2 Milk Company (ASX:A2M) has guided to mid-single-digit FY27 revenue growth, an EBITDA margin of approximately 15%, capital expenditure near NZD 70mn and cash conversion of roughly 70–80%. Management expects revenue and EBITDA to be weighted toward 2HFY27 as formula supply recovers. Its scheduled November 2026 annual meeting is expected to provide an update on the infant formula recovery plan, followed by the 1HFY27 results in February 2027.
Key Insights
FY26 brought higher revenue but lower reported EBITDA and profit for The a2 Milk Company (ASX:A2M). Liquid milk and other nutritionals grew while formula supply disruption affected China-label operations. Subsequent financial performance will depend on product availability, the Pōkeno transition, regional sales execution and the timing of recovery anticipated in FY27 guidance.


_11_19_2026_18_25_09_904658.jpg)



Please wait processing your request...